Vivante Health scoops up $31m for its cutting-edge digital digestive platform

Vivante Health scoops up $31m for its cutting-edge digital digestive platform

Vivante Health, dubbed as the frontrunner in the world of digital digestive health, has successfully wrapped up a significant $31m Series B funding round.

The principal investor behind this substantial backing is Mercato Partners. Additionally, new financial support also poured in from Health Catalyst Capital. Esteemed previous investors, such as 7wireVentures, Intermountain Ventures, Distributed Ventures, Human Capital, and SemperVirens, have shown continued faith in the GIThrive platform’s capacity to upscale patient results and provide a substantial reduction in medical expenses.

Vivante Health has introduced revolutionary enhancements to its GIThrive platform, particularly emphasising its distinctive capability to offer timely and appropriate care. Apart from resources like food symptom documentation and educational content available online, the platform now offers 24/7 consultations with dietitians, health mentors, and nursing staff. Furthermore, users are privy to AI-based customised care blueprints, access to a vast network of internists and gastroenterologists, and numerous other services bridging the chasm between virtual and in-person medical care.

The fresh influx of Series B funds aims to propel further technological enhancements, forecasting the beginning and evolution of GI issues and delivering comprehensive virtual care for digestive ailments. Additionally, this capital injection will bolster the company’s ongoing growth strategies, facilitating the broadening of its commercial and client aid teams and streamlining the integration process for new employers and health schemes.

Vivante Health CEO Bill Snyder shared his enthusiasm, “We are thrilled to have the support of industry-leading capital partners as we execute on our vision at Vivante. One in four Americans suffers from a digestive disorder or undiagnosed digestive symptoms that affect their quality of life as well as their healthcare costs. We have proven that our scalable technology platform paired with our comprehensive care team results in better health, lower costs, and a much better experience for the members we serve.”

GIThrive’s exceptional provision of care spans across a broad spectrum of digestive diseases, ranging from more prevalent conditions like IBS to intricate ailments such as Inflammatory Bowel Disease necessitating intricate care coordination. An impressive 90% of GIThrive’s users acknowledge the platform’s resourcefulness, expressing significant relief from digestive symptoms and an overall enhancement in their quality of life.

Vivante’s robust growth trajectory in the competitive health benefits domain is undeniable, evidenced by its acceptance by leading Fortune 500 firms and its collaboration with predominant health plans.

Joe Kaiser, a Managing Director at Mercato Partners, lauded Vivante’s innovative approach, “Vivante is reinventing the management of chronic gut conditions through its ‘right care at the right time’ triage methodology. This approach to patient-centric, digital GI management bridges the gap that exists between generalist and specialist care, giving patients back time, money, and quality of life lost to gastrointestinal issues as well as delivering a compelling ROI to employers.”

It’s noteworthy that prior to this Series B round, Vivante had already amassed $16m in a Series A investment round in the latter part of 2021.

Keep up with all the latest FinTech news here

Copyright © 2023 FinTech Global

Enjoying the stories?

Subscribe to our daily FinTech newsletter and get the latest industry news & research


The following investor(s) were tagged in this article.